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Abstract: Introduction: There is still controversy over the existence of a relation between hypothyroidism and fatty liver
disease. The scale by which hypothyroidism can affect fatty liver disease progression is also to be determined.
Therefore, our study aims to contribute in the determination of this relation. Materials and methods: This ob-
servational analytical-before and after study with 53 patients was conducted. The subjects were categorized as
having either primary or subclinical hypothyroidism. The serum levels of thyroid stimulation hormone (TSH),
free T3 (FT3), free T4 (FT4), alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phos-
phatase (ALP) were measured and liver ultrasound was done to screen nonalcoholic fatty liver disease (NAFLD).
Results: The study consisted of 41 women and 12 men with the mean age of 48.3 years. The mean TSH levels
decreased after hypothyroidism treatment in patients. The mean levels of FT4 did not have a significant increase
after treatment, although in patients with subclinical hypothyroidism this increase was significant. T3 levels in-
creased significantly after treatment. Statistical studies showed that there was a significant change in the degree
of fatty liver before and after hypothyroidism treatment. Conclusion: There was an explicit relation between
hypothyroidism and non-alcoholic fatty liver disease as Hypothyroidism treatment can prevent non-alcoholic
fatty liver disease progression.
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1. Introduction
In recent decades, with the rapid advancement of technol-
ogy and lifestyle changes, the face of common diseases has
changed from infections to emerging diseases. One of these
diseases is non- alcoholic fatty liver disease (NAFLD) and cir-
rhosis and liver failure as a result.
Non-alcoholic steatohepatitis (NASH) is a title for a clinical
topic in which patients, without a clear history of alcohol
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use, have indistinguishable findings from alcoholic steato-
hepatitis in their liver biopsy specimens(1, 2). The preva-
lence of NASH in the general population has not been well
established(3). This limitation is due to sensitivity limita-
tions in non-invasive NASH diagnostic evaluation methods.
The prevalence of NAFLD can be better assessed in the com-
munity, because it can be detected by non-invasive methods.
Fatty liver has become a common disorder in western indus-
trialized societies, affecting 20 to 40% of the population(4).
Fatty liver disease is more common around puberty(5, 6).
NAFLD and NASH are more common in men(6, 7), perhaps
due to the fact that men are more likely to develop metabolic
syndrome. The main risk factors for NAFLD include: central
obesity, type 2 diabetes, dyslipidemia, and metabolic syn-
drome.
Hypothyroidism is the most common endocrine disease af-
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ter diabetes. It occurs when the thyroid gland is unable
to produce enough hormones. Hypothyroidism is classi-
fied into primary hypothyroidism (symptomatic hypothy-
roidism) and subclinical hypothyroidism (asymptomatic hy-
pothyroidism), secondary hypothyroidism (pituitary) and
tertiary hypothyroidism (Hypothalamic). (7-10) The Clinical
signs of hypothyroidism are very diverse. It depends on the
age of onset, the duration of the infection, and the severity of
the hormone deficiency.
Symptoms such as fatigue, cold intolerance, weight gain,
constipation, myalgia and Menstrual irregularities are com-
mon among people with hypothyroidism. Diagnosis of hy-
pothyroidism is based on lab test results. (11-13)
There are few studies on the direct effect of hypothyroidism
on the incidence of NASH, however, these studies suggest
that hypothyroidism may cause NASH through hyperlipi-
demia and obesity. (14, 15) In this study, we intend to inves-
tigate the effect of primary hypothyroidism treatment on this
common disease by examining the changes in the severity
of fatty liver before and after treatment of primary hypothy-
roidism in patients referred to Imam Hossein Hospital.
2. Materials and Methods
This observational analytical-before and after study was per-
formed in the endocrinology clinic of Imam Hossein Medical
Center. At the clinic, patients who had not received treatment
due to hypothyroidism, were given full explanations about
the present study and its objectives, and were invited to par-
ticipate in the research project with written consent.
Patients were given questionnaires regarding these comor-
bidities: smoking, history of cardiovascular disease, hyper-
lipidemia and hypertension. The patients’ age was also in-
cluded in their information form and their body mass in-
dex (BMI) was then calculated as follows: BMI=body weight
(kg)/height squared (m2). Exclusion criteria from this study
included history of hypothyroidism treatment, history of
fatty liver treatment, diagnosis or development of fatty liver
disease, history of regular alcohol consumption, use of liver
dysfunction drugs, hepatitis B & C and cirrhosis.
Finally, 53 patients, including 12 men and 41 women were
have been included, who they did not meet the exclusion cri-
teria and were willing to participate in this study . For these
patients, tests were performed to determine the serum levels
of TSH, FT3, FT4, ALT, AST and ALP, and liver ultrasound was
performed by a specialist to determine the presence of fatty
liver and its severity for these patients. After 8 weeks of start-
ing hypothyroidism treatment, TSH, FT3 and FT4 tests were
performed again to adjust the dose of the drug, and if these
tests were normal, after 3 months, TSH, FT3, FT4, ALT, AST
and ALP tests and liver ultrasound were performed and then
patients’ information was entered in a form for statistical ex-
aminations.
For statistical analysis, SPSS software version 16 was used.
Analysis of qualitative variables was performed by ANOVA,
Chi2, Wilcoxon signed rank and Friedman tests and quanti-
tative variables were analyzed by T-test. The acceptable al-
pha error was considered to be 0.05 and the beta error was
considered to be 0.2.
All researchers of this study heed the Declaration of Helsinki.
And the patient’s names amongst their other personal infor-
mation are confidential and no payment was received from
the patients.
3. Results
In this study, 53 patients with newly diagnosed primary hy-
pothyroidism who had not yet received treatment were stud-
ied. The study looked at 41 women and 12 men between the
ages of 21 and 73 and the mean age of these patients was 48.3
years. 20 patients had subclinical hypothyroidism and 33 pa-
tients had primary hypothyroidism.
The review of the patients’ files showed that 24 of the patients
did not have comorbidities, 29 people had at least one form
of hypertension, cardiovascular disease, and HLP, of which
HLP was the most common.
In general, the mean TSH levels before and after hypothy-
roidism in patients were 13.43± 8.41 and 3.80 ±1.60 respec-
tively, which statistically decreased TSH levels after treat-
ment. (P <0.05). The mean levels of FT4 before and after
hypothyroidism in patients were 1.49±1.16 and 1.55±1.25 re-
spectively, which did not have a statistically significant in-
crease after treatment, although in patients with subclinical
hypothyroidism this increase is significant.
Among all patients, T3 levels before and after hypothy-
roidism treatment were 72.61±14.18 and 90.35±15.62 respec-
tively, and statistically, T3 levels increased significantly after
treatment. (P <0.05)
Figure 1 shows the frequency of different degrees of fatty liver
before hypothyroidism treatment. Grade 1 fatty liver is more
common than other degrees, and Figure 2 shows the fre-
quency of different degrees of fatty liver after hypothyroidism
treatment. At this stage, grade 1 fatty liver is still more com-
mon and the number of people with grade 1 fatty liver has
increased. Statistical studies showed that there was a signif-
icant change in the degree of fatty liver before and after hy-
pothyroidism treatment. In general, in 12 patients the degree
of fatty liver decreased, in 41 patients there was no change
and in none of the patients there was an increase in the de-
gree of fatty liver.
ALT levels before and after hypothyroidism treatment were
42.15±21.84 and 39.26±18.14 respectively, which did not
show a statistically significant decrease after treatment.
ALP levels before and after hypothyroidism in patients were
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60.03±1.57 and 40.11±1.59 respectively, indicating no signifi-
cant change in its level after hypothyroidism.
In the study population, AST levels before and after hypothy-
roidism treatment were 37.67±16.62 and 34.07±13.74 respec-
tively, indicating a decrease in the level of patients after hy-
pothyroidism treatment.
Patients’ BMI decreased generally after hypothyroidism,
so that the mean was 30.67±5.31 before treatment and
29.95±5.28 after treatment. Studies also showed that 21 peo-
ple were non-smokers, 10 were smokers, 17 were inactive
smokers and 5 were already smokers.
4. Discussion
Non-alcoholic fatty liver disease is among the prevalent
causes of chronic hepatitis and cirrhosis; on the other hand,
hypothyroidism is a condition affecting lifelong health in pa-
tients. As these two conditions are common health issues af-
fecting the quality of lives of many patients, studying the as-
sociation between them could result in significant findings.
Currently, there are not enough studies on the direct effect of
hypothyroidism on NAFLD. In this study, the rate of change
in the severity of fatty liver disease before and after treatment
of hypothyroidism in patients referred to Imam Hossein Hos-
pital has been investigated. Our study suggests significant
impact of hypothyroidism treatment on the suppression of
fatty liver disease.
Liver enzymes (AST, ALT, and ALP) are found in liver cells and
released into the patient’s serum after a damage to the liver
tissue. Therefore, the increase in AST, ALT, and ALP serum
levels shows the destruction of liver cells (16). In this study an
insignificant decrease in ALT and ALP levels and a significant
decrease in AST levels was seen which shows a decrease in
the liver tissue damage. Although some of these enzymes did
not appear to have significant decrease in their serum levels,
data depicts the process of liver damage to be restricted.
The average BMI of patients significantly decreased after the
treatment of hypothyroidism. One study shows a meaningful
relation between BMI and NAFLD (17). A study demonstrates
that hypothyroidism can cause hyperlipidemia and obesity
and thereby cause NASH. Hence, the decline in BMI can be
effective in the suppression of liver damage (14).
As obesity, hypertension, type II diabetes, and other
metabolic disorders have an important role in the increased
risk of NAFLD, regular physical activity and exercise, and a
low-fat diet is recommended to reduce the risk of NAFLD and
liver damage (18). Many studies show a change in lifestyle,
especially weight loss and increased physical activity, has an
explicit effect on the improvement of NAFLD stage (19).
Another study also found a significant difference between
the liver enzyme levels of patients with hypothyroidism
and the patients with normal thyroid function. This study
also shows a dose-dependent relation between the hypothy-
roidism spectrum and NAFLD. Several other studies also
confirm these findings. (20-23)
There is also an opposing study which states that there is no
association between hypothyroidism and fatty liver disease.
This study has reviewed different articles and therefore its re-
sults could be compromised by statistical heterogenicity. The
study also mentions that its result could be due to the limita-
tion of races that have been assessed up to now, consisting of
only Caucasians and Asians. (24)
Our study not only shows a relation between hypothyroidism
and NAFLD, but also measures the impact. Therefore, this
study provides quantitative information on the association.
Furthermore, TSH, T3, FT4, AST, ALT, and ALP levels were all
assessed in this study which is an advantage amongst some
of the other similar articles.
In this study, certain comorbidities-which were mentioned
earlier- were considered as potential interfering factors, and
thus have been included in the gathering of data. Passive
smoking has also been considered in our study as a comor-
bidity.
Our study was carried out on patients newly diagnosed with
hypothyroidism, which is an advantage amongst other sim-
ilar studies. Moreover, to our knowledge this study was the
first to measure the association between hypothyroidism and
fatty liver disease in its own population; which can help pro-
vide information about Middle Eastern people as well, and
therefore confirm the previous studies on a new population.
Limitations of our study include; the use of imaging tech-
niques for screening of NAFLD, instead of liver biopsy –which
is the gold standard- could fault the results to some extent, all
the laboratory tests were carried out in one (but reliable) clin-
ical laboratory so further study is still needed on the matter,
especially in different populations and races.
5. Conclusion
Our study demonstrates a significant association between
hypothyroidism and fatty liver disease. Hypothyroidism
causes the progression of NAFLD by increasing the risk of hy-
perlipidemia and obesity. Therefore, hypothyroidism treat-
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Figure 1: Shows the frequency of different degrees of fatty liver before hypothyroidism treatment.
Figure 2: Shows the frequency of different degrees of fatty liver after hypothyroidism treatment.
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